{"id":10124,"date":"2020-12-03T14:37:55","date_gmt":"2020-12-03T05:37:55","guid":{"rendered":"http:\/\/cell.brc.riken.jp\/en\/?page_id=10124"},"modified":"2024-06-03T14:07:52","modified_gmt":"2024-06-03T05:07:52","slug":"patient_specific_ips","status":"publish","type":"page","link":"http:\/\/cell.brc.riken.jp\/en\/hps\/patient_specific_ips","title":{"rendered":"Disease-specific iPS cells"},"content":{"rendered":"

\uff0a When you want to use some Disease-specific iPS cells, please e-mail to the following address.
\n\uff0a In relation to the information that are not described below, please e-mail to the following address.<\/p>\n

Contact us :\u00a0cellips.brc\"\"riken.jp<\/a><\/p>\n

Blue letter cells are available. You obtain the information by clicking the blue letter.
\n*iPS cells created using the Sendai virus vector are now available<\/a><\/p>\n

Genetic analysis of disease-specific iPS cells carried out in RIKEN BRC.
\n\u30fbAmyotrophic lateral sclerosis (ALS)<\/a>
\n\u30fbSpinocerebellar degeneration<\/a><\/p>\n

*Terms:
\nIn relation to all iPS cell lines, approval of institutional review board and\/or institutional ethical committee regarding the research using iPS cells is necessary.
\nIn relation to all iPS cell lines, commercial use is prohibited.
\nIn relation to the cell lines marked with \u25ce, (1) the recipient does not need to obtain an approval from the depositor, (2) there is no need of collaboration with the depositor, and (3) for-profit entities can also utilize.<\/p>\n

Update : 2020.11.27
\n

Disease group<\/span>Neuromuscular diseases<\/span>Metabolic diseases<\/span>Skin and connective tissue diseases<\/span>Immune diseases<\/span>Circulatory system diseases<\/span>Hematologic diseases<\/span>Kidney and urologic diseases<\/span>Bone, cartilage, and articular diseases<\/span>Endocrine diseases<\/span>Respiratory tract diseases<\/span>Eye diseases<\/span>Otorhinolaryngologic diseases<\/span>Digestive system diseases<\/span>Diseases due to chromosomal aberrations and gene mutations<\/span>Other diseases<\/span>Healthy relatives of patients<\/span>Healthy individuals (Clinical information is available only for users in Japan)<\/span>Healthy individuals<\/span><\/div>
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Disease group<\/th>\nDiseases<\/th>\nPatients<\/th>\nCell line<\/th>\n<\/tr>\n
Neuromuscular diseases<\/span><\/strong><\/td>\n62<\/td>\n305<\/td>\n1201 <\/i><\/td>\n<\/tr>\n
Metabolic diseases<\/span><\/strong><\/td>\n9<\/td>\n40<\/td>\n168 <\/i><\/td>\n<\/tr>\n
Skin and connective tissue diseases<\/span><\/strong><\/td>\n8<\/td>\n23<\/td>\n126<\/td>\n<\/tr>\n
Immune diseases<\/span><\/strong><\/td>\n23<\/td>\n53<\/td>\n25<\/td>\n<\/tr>\n
Circulatory system diseases<\/span><\/strong><\/td>\n3<\/td>\n28<\/td>\n60 <\/i><\/td>\n<\/tr>\n
Hematologic diseases<\/span><\/strong><\/td>\n8<\/td>\n26<\/td>\n128 <\/i><\/td>\n<\/tr>\n
Kidney and urologic diseases<\/span><\/strong><\/td>\n7<\/td>\n17<\/td>\n67 <\/i><\/td>\n<\/tr>\n
Bone, cartilage, and articular diseases<\/span><\/strong><\/td>\n11<\/td>\n41<\/td>\n126<\/td>\n<\/tr>\n
Endocrine diseases<\/span><\/strong><\/td>\n9<\/td>\n25<\/td>\n130<\/td>\n<\/tr>\n
Respiratory tract diseases<\/span><\/strong><\/td>\n9<\/td>\n19<\/td>\n106<\/td>\n<\/tr>\n
Eye diseases<\/span><\/strong><\/td>\n4<\/td>\n15<\/td>\n26<\/td>\n<\/tr>\n
Otorhinolaryngologic diseases<\/span><\/strong><\/td>\n1<\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
Digestive system diseases<\/span><\/strong><\/td>\n8<\/td>\n19<\/td>\n114 <\/i><\/td>\n<\/tr>\n
Diseases due to chromosomal aberrations and gene mutations<\/span><\/strong><\/td>\n18<\/td>\n25<\/td>\n118<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Other diseas<\/span><\/strong><\/td>\n51<\/td>\n116<\/td>\n476<\/td>\n<\/tr>\n
<\/td>\n<\/td>\n<\/td>\n<\/td>\n<\/tr>\n
Total<\/span><\/strong><\/td>\n231<\/td>\n753<\/td>\n3110<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n\n\n\n
<\/th>\nDiseases<\/th>\nPatients<\/th>\nCell line<\/th>\n<\/tr>\n
Healthy relatives of patients<\/span><\/strong><\/td>\n9<\/td>\n13<\/td>\n64<\/td>\n<\/tr>\n
Healthy individuals
\n(Clinical information is available only for users in Japan)<\/span><\/strong><\/td>\n		<\/td>\n58<\/td>\n343<\/td>\n<\/tr>\n
Healthy individuals<\/span><\/strong><\/td>\n<\/td>\n59<\/td>\n311<\/td>\n<\/tr>\n
Total<\/span><\/strong><\/td>\n9<\/td>\n130<\/td>\n718<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nNeuromuscular diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nSpinal-Bulbar Muscular Atrophy (SBMA)<\/a> <\/span><\/strong><\/td>\n3<\/td>\n12<\/td>\n<\/tr>\n
2<\/td>\nAmyotrophic lateral sclerosis (ALS)<\/a> <\/span><\/strong><\/td>\n67<\/td>\n256<\/td>\n<\/tr>\n
3<\/td>\nSpinal muscular atrophy <\/a> <\/span><\/strong><\/td>\n4<\/td>\n16<\/td>\n<\/tr>\n
4<\/td>\nPrimary lateral sclerosis (PLS)<\/a> <\/span><\/strong><\/td>\n3<\/td>\n10<\/td>\n<\/tr>\n
5<\/td>\nProgressive supranuclea palsy (PSP)<\/a>\u00a0 <\/span><\/strong><\/td>\n1<\/td>\n5<\/td>\n<\/tr>\n
6<\/td>\nParkinson\u2019s disease (PD)<\/a><\/span><\/strong><\/td>\n8<\/td>\n34<\/td>\n<\/tr>\n
7<\/td>\nCorticobasal degeneration (CBD)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
8<\/td>\nHuntington\u2019s disease<\/a> <\/strong><\/span><\/td>\n2<\/td>\n7<\/td>\n<\/tr>\n
9<\/td>\nCharcot-Marie-Tooth disease<\/a> <\/span><\/strong><\/td>\n11<\/td>\n23<\/td>\n<\/tr>\n
10<\/td>\nMyasthenia Gravis (MG)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
11<\/td>\nCongenital myasthenic syndrome<\/a> <\/span><\/strong><\/td>\n7<\/td>\n27<\/td>\n<\/tr>\n
12<\/td>\nMultiple sclerosis (MS) \/ Neuromyelitis Optica Spectrum Disorders (NMOSD)<\/a> <\/span><\/strong><\/td>\n4<\/td>\n24<\/td>\n<\/tr>\n
13<\/td>\nChronic inflammatory demyelinating polyneuropathy (CIDP) \/ multifocal motor neuropathy (MMN)<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
14<\/td>\nInclusion body myositis <\/a> <\/span><\/strong><\/td>\n2<\/td>\n4<\/td>\n<\/tr>\n
15<\/td>\nCrow\u2010Fukase syndrome <\/a> <\/span><\/strong><\/td>\n2<\/td>\n10<\/td>\n<\/tr>\n
16<\/td>\nMultiple system atrophy (MSA)<\/a> <\/span><\/strong><\/td>\n6<\/td>\n19<\/td>\n<\/tr>\n
17<\/td>\nSpinocerebellar Degeneration<\/a><\/span><\/strong><\/td>\n30<\/td>\n104<\/td>\n<\/tr>\n
18<\/td>\nMoyamoya disease<\/a><\/span><\/strong><\/td>\n4<\/td>\n21<\/td>\n<\/tr>\n
19<\/td>\nSubacute sclerosing panencephalitis (SSPE)<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
20<\/td>\nProgressive multifocal leukoencephalopathy (PML)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n5<\/td>\n<\/tr>\n
21<\/td>\nFahr disease<\/a> <\/span><\/strong><\/td>\n7<\/td>\n17 <\/i><\/td>\n<\/tr>\n
22<\/td>\nUllrich congenital muscular dystrophy<\/a> <\/span><\/strong><\/td>\n2<\/td>\n4<\/td>\n<\/tr>\n
23<\/td>\nDistal Myopathy<\/a> <\/span><\/strong><\/td>\n9<\/td>\n42<\/td>\n<\/tr>\n
24<\/td>\nBethlem myopathy<\/a><\/span><\/strong><\/td>\n3<\/td>\n11<\/td>\n<\/tr>\n
25<\/td>\nDanon disease<\/a><\/span><\/strong><\/td>\n2<\/td>\n2<\/td>\n<\/tr>\n
26<\/td>\nSchwartz-Jampel syndrome (SJS)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
27<\/td>\nCongenital myopathy <\/a> <\/span><\/strong><\/td>\n4<\/td>\n15<\/td>\n<\/tr>\n
28<\/td>\nMuscular dystrophy <\/a> <\/span><\/strong><\/td>\n31<\/td>\n107<\/td>\n<\/tr>\n
29<\/td>\nPeriodic paralysis<\/a> <\/span><\/strong><\/td>\n1<\/td>\n4<\/td>\n<\/tr>\n
30<\/td>\nSyringomyelia<\/a> <\/span><\/strong><\/td>\n1<\/td>\n5<\/td>\n<\/tr>\n
31<\/td>\nIsaacs syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
32<\/td>\nHereditary dystonia<\/a> <\/span><\/strong><\/td>\n4<\/td>\n13<\/td>\n<\/tr>\n
33<\/td>\nNeuroferritinopathy<\/a><\/span><\/strong><\/td>\n1<\/td>\n1<\/td>\n<\/tr>\n
34<\/td>\nCerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy(CADASIL)<\/a><\/span><\/strong><\/td>\n7<\/td>\n7<\/td>\n<\/tr>\n
35<\/td>\nPerry syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
36<\/td>\nFrontotemporal lobar degeneration (FTLD) <\/a><\/span><\/strong><\/td>\n3<\/td>\n14<\/td>\n<\/tr>\n
37<\/td>\nAcute encephalopathy with biphasic seizures and late reduced diffusion (AESD)\u00a0<\/a><\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
38<\/td>\nCongenital insensitivity to pain with anhidrosis <\/a> <\/span><\/strong><\/td>\n2<\/td>\n8<\/td>\n<\/tr>\n
39<\/td>\nAlexander disease <\/a> <\/span><\/strong><\/td>\n5<\/td>\n25<\/td>\n<\/tr>\n
40<\/td>\nAicardi syndrome <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
41<\/td>\nHemimegalencephaly <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
42<\/td>\nFocal cortical dysplasia (FCD) <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
43<\/td>\nNeuronal migration disorder <\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
44<\/td>\nDravet syndrom<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
45<\/td>\nMesial temporal lobe epilepsy with hippocampal sclerosis<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
46<\/td>\nEpilepsy with myoclonic absence (EMA)<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
47<\/td>\nEpilepsy with myoclonic-astatic seizures<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
48<\/td>\nLennox-Gastaut syndrome (LGS)<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
49<\/td>\nWest syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
50<\/td>\nOhtahara syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
51<\/td>\nHemiconvulsion-hemiplegia-epilepsy syndrome<\/a><\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
52<\/td>\nRing chromosome 20 syndrome<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12 <\/i><\/td>\n<\/tr>\n
53<\/td>\nRasmussen encephalitis<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
54<\/td>\nPCDH19 epilepsy<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
55<\/td>\nEpilepsy with continuous spikes and waves during slow sleep<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
56<\/td>\nLandau\u2015Kleffner syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
57<\/td>\nRett syndrome<\/a> <\/span><\/strong><\/td>\n6<\/td>\n36 <\/i><\/td>\n<\/tr>\n
58<\/td>\nSturge-Weber syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
59<\/td>\nTuberous sclerosis complex (TSC)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6 <\/i><\/td>\n<\/tr>\n
60<\/td>\nXeroderma pigmentosum<\/a> <\/span><\/strong><\/td>\n5<\/td>\n18<\/td>\n<\/tr>\n
61<\/td>\nAngelman syndrome<\/a> <\/span><\/strong><\/td>\n11<\/td>\n26<\/td>\n<\/tr>\n
62<\/td>\nGlycosylphosphatidylinositol(GPI) anchor deficiency<\/a>\u00a0<\/span><\/strong><\/td>\n3<\/td>\n17<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n305<\/td>\n1201<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nMetabolic diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nlysosomal storage disease <\/a> <\/span><\/strong><\/td>\n17<\/td>\n81<\/td>\n<\/tr>\n
2<\/td>\nAdrenoleukodystrophy (ALD) <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12 <\/i><\/td>\n<\/tr>\n
3<\/td>\nMitochondrial diseases <\/a> <\/span><\/strong><\/td>\n6<\/td>\n16<\/td>\n<\/tr>\n
4<\/td>\nAmyloid neuropathy, <\/a> <\/span><\/strong><\/td>\n4<\/td>\n17<\/td>\n<\/tr>\n
5<\/td>\nWilson\u2019s disease <\/a> <\/span><\/strong><\/td>\n4<\/td>\n18<\/td>\n<\/tr>\n
6<\/td>\nPhenylketonuria <\/a><\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
7<\/td>\nOrnithine transcarbamylase deficiency (OTCD <\/a><\/span><\/strong><\/td>\n1<\/td>\n1<\/td>\n<\/tr>\n
8<\/td>\nGlycogen storage disease<\/a> <\/span><\/strong><\/td>\n3<\/td>\n15<\/td>\n<\/tr>\n
9<\/td>\nGlycogen storage disease<\/a> <\/span><\/strong><\/td>\n2<\/td>\n4<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n40<\/td>\n168<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nSkin and connective tissue diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nNeurofibromatosis<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
2<\/td>\nPemphigus<\/a> <\/span><\/strong><\/td>\n4<\/td>\n24<\/td>\n<\/tr>\n
3<\/td>\nPustular psoriasis<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
4<\/td>\nStevens-Johnson syndrome (SJS)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
5<\/td>\nSystemic sclerosis (SSc)<\/a> <\/span><\/strong><\/td>\n7<\/td>\n36<\/td>\n<\/tr>\n
6<\/td>\nCongenital ichthyosis<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
7<\/td>\nPemphigoid<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
8<\/td>\nEhlers-Danlos syndrome<\/a> <\/span><\/strong><\/td>\n3<\/td>\n12<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n23<\/td>\n126<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nImmune diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nTakayasu arteritis <\/a> <\/span><\/strong><\/td>\n4<\/td>\n24<\/td>\n<\/tr>\n
2<\/td>\nGiant cell arteritis (GCA) <\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
3<\/td>\nPolyarteritis nodosa (PAN) <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
4<\/td>\nMicroscopic polyangiitis \uff08MPA) <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
5<\/td>\nGranulomatosis with polyangiitis (GPA) <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
6<\/td>\nEosinophilic granulomatosis with polyangiitis (EGPA) <\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
7<\/td>\nMalignant rheumatoid arthritis (MRA) <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
8<\/td>\nBuerger\u2019s disease <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
9<\/td>\nPrimary antiphospholipid syndrome, APS with venous and <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
10<\/td>\nSystemic lupus erythematosus (SLE) <\/a> <\/span><\/strong><\/td>\n5<\/td>\n16<\/td>\n<\/tr>\n
11<\/td>\nDermatomyositis (DM)\/Polymyositis (PM)<\/a> <\/span><\/strong><\/td>\n7<\/td>\n18<\/td>\n<\/tr>\n
12<\/td>\nMixed Connective-Tissue Disease (MCTD)<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
13<\/td>\nSj\u00f6gren\u2019s syndrome <\/a> <\/span><\/strong><\/td>\n2<\/td>\n10<\/td>\n<\/tr>\n
14<\/td>\nAdult-onset Still\u2019s disease (AOSD)<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
15<\/td>\nRelapsing polychondritis (RP)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
16<\/td>\nBeh\u00e7et\u2019s disease<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
17<\/td>\nChronic infantile neurological cutaneous and articular syndrome (CINCA syndrome) <\/a><\/span><\/strong><\/td>\n2<\/td>\n3<\/td>\n<\/tr>\n
18<\/td>\nTNF receptor-associated periodic syndrome\u00a0<\/a><\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
19<\/td>\nFamilial Mediterranean fever<\/a><\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
20<\/td>\nNakajo-Nishimura Syndrome <\/a> <\/span><\/strong><\/td>\n2<\/td>\n2<\/td>\n<\/tr>\n
21<\/td>\nPyogenic sterile arthritis, pyoderma gangrenosum and acne syndrome\u00a0<\/a><\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
22<\/td>\nIgG4-related disease<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
23<\/td>\nEosinophilic sinusitis<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n53<\/td>\n259<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nCirculatory system diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nDilated cardiomyopathy (DCM) <\/a> <\/span><\/strong><\/td>\n17<\/td>\n34<\/td>\n<\/tr>\n
2<\/td>\nHypertrophic cardiomyopathy (HCM) <\/a> <\/span><\/strong><\/td>\n8<\/td>\n18<\/td>\n<\/tr>\n
3<\/td>\nTricuspid atresia <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n28<\/td>\n60<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nHematologic diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nAplastic anemi <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
2<\/td>\nAutoimmune hemolytic anemia (AHA)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
3<\/td>\nParoxysmal nocturnal hemoglobinuria (PNH) <\/a> <\/span><\/strong><\/td>\n3<\/td>\n16<\/td>\n<\/tr>\n
4<\/td>\nIdiopathic thrombocytopenic purpura <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
5<\/td>\nThrombotic thrombocytopenic purpura (TTP) <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
6<\/td>\nPrimary immunodeficiency syndrome (PIDS)<\/a> <\/span><\/strong><\/td>\n13<\/td>\n48<\/td>\n<\/tr>\n
7<\/td>\nDiamond-Blackfan anemia<\/a> <\/span><\/strong><\/td>\n3<\/td>\n26<\/td>\n<\/tr>\n
8<\/td>\nFanconi anemia <\/a> <\/span><\/strong><\/td>\n2<\/td>\n8<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n26<\/td>\n128<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nKidney and urologic diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nIgA nephropathy<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
2<\/td>\nPolycystic Kidney disease<\/a> <\/span><\/strong><\/td>\n9<\/td>\n24 <\/i><\/td>\n<\/tr>\n
3<\/td>\nAtypical hemolytic uremic syndrome (aHUS)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
4<\/td>\nGalloway-Mowat syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n1<\/td>\n<\/tr>\n
5<\/td>\nRapidly progressive glomerulonephritis<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
6<\/td>\nAnti-glomerular basement membrane antibody (GBM)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
7<\/td>\nPrimary nephrotic syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6 <\/i><\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n17<\/td>\n67<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nBone, cartilage, and articular diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nOssification of the yellow ligament (OYL)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
2<\/td>\nOssification of posterior longitudinal ligament<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
3<\/td>\nSpinal stenosis<\/a> <\/span><\/strong><\/td>\n1<\/td>\n4<\/td>\n<\/tr>\n
4<\/td>\nIdiopathic osteonecrosis of femoral Head<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
5<\/td>\nHypophosphatasia<\/a> <\/span><\/strong><\/td>\n3<\/td>\n8<\/td>\n<\/tr>\n
6<\/td>\nVitamin D resistant rickets \/ Osteomalacia<\/a> <\/span><\/strong><\/td>\n2<\/td>\n7<\/td>\n<\/tr>\n
7<\/td>\n\uff21nkylosing spondylitis<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
8<\/td>\nFibrodysplasia ossificans progressiva (FOP)<\/a> <\/span><\/strong><\/td>\n2<\/td>\n3<\/td>\n<\/tr>\n
9<\/td>\nOsteogenesis Imperfecta <\/a> <\/span><\/strong><\/td>\n12<\/td>\n33<\/td>\n<\/tr>\n
10<\/td>\n\uff34hanatophoric dysplasi <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
11<\/td>\nAchondroplasia<\/a> <\/span><\/strong><\/td>\n16<\/td>\n41<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n41<\/td>\n126<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nEndocrine diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nDisorders of pituitary ADH secretion<\/a> <\/span><\/strong><\/td>\n6<\/td>\n25<\/td>\n<\/tr>\n
2<\/td>\nPituitary hypersecretion of TSH<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
3<\/td>\nHyperprolactinemia<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
4<\/td>\nPituitary hypersecretion of growth hormon<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
5<\/td>\nHypopituitarism<\/a> <\/span><\/strong><\/td>\n8<\/td>\n39<\/td>\n<\/tr>\n
6<\/td>\nResistance to Thyroid Hormone<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
7<\/td>\nCongenital Adrenal enzyme deficiency<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
8<\/td>\nAddison\u2019s disease<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
9<\/td>\nHypoparathyroidism<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n25<\/td>\n130<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nRespiratory tract diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nSarcoidosis <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
2<\/td>\nIdiopathic interstitial pneumonia <\/a> <\/span><\/strong><\/td>\n3<\/td>\n13<\/td>\n<\/tr>\n
3<\/td>\nPulmonary hypertension <\/a> <\/span><\/strong><\/td>\n4<\/td>\n21<\/td>\n<\/tr>\n
4<\/td>\nPulmonary veno-occlusive disease \/ pulmonary capillary hemangiomatosis <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
5<\/td>\nIdiopathic chronic pulmonary thromboembolism with pulmonary hypertension <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
6<\/td>\nLymphangioleiomyomatosis <\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
7<\/td>\nPulmonary alveolar proteinosis (PAP)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
8<\/td>\nAlveolar hypoventilation syndrome (AHS) <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
9<\/td>\nCongenital diaphragmatic hernia <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n19<\/td>\n106<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nEye diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nRetinitis pigmentosa<\/a><\/span><\/strong><\/td>\n8<\/td>\n12<\/td>\n<\/tr>\n
2<\/td>\nMacular degeneration<\/a> <\/span><\/strong><\/td>\n3<\/td>\n9<\/td>\n<\/tr>\n
3<\/td>\nLeber Hereditary Optic Neuropathy<\/a> <\/span><\/strong><\/td>\n3<\/td>\n3<\/td>\n<\/tr>\n<\/tr>\n
4<\/td>\nGelatinous drop-like corneal dystrophy<\/a> <\/span><\/strong><\/td>\n1<\/td>\n2<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n15<\/td>\n26<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nOtorhinolaryngologic diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nBranchio-oto-renal syndrome<\/a><\/span><\/strong><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nDigestive system diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nPrimary biliary cirrhosis (PBC) <\/a> <\/span><\/strong><\/td>\n5<\/td>\n30<\/td>\n<\/tr>\n
\uff12<\/td>\nPrimary sclerosing cholangitis (PSC)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
\uff13<\/td>\nAutoimmune hepatitis (AIH) <\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
\uff14<\/td>\nCrohn\u2019s disease <\/a> <\/span><\/strong><\/td>\n4<\/td>\n24<\/td>\n<\/tr>\n
\uff15<\/td>\nUlcerative colitis <\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
\uff16<\/td>\nEosinophilic \uff47astro-intestinal disorde <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
\uff17<\/td>\nhronic nonspecific multiple ulcers of the small intestine<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
8<\/td>\nHirschsprung\u2019s disease <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n19<\/td>\n114<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nDiseases due to chromosomal aberrations and gene mutations<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
2<\/td>\nRubinstein-Taybi syndrom <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
2<\/td>\nCFC syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
3<\/td>\nPachydermoperiostosis, possible case<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
4<\/td>\nWilliams syndrome\u00a0<\/a><\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
5<\/td>\nATR-X syndrome <\/a><\/span><\/strong><\/td>\n2<\/td>\n5<\/td>\n<\/tr>\n
6<\/td>\nCoffin-Siris syndrome <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
7<\/td>\nKabuki syndrome\u00a0<\/a><\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
8<\/td>\nWerner syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
9<\/td>\nCockayne\u2019s syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n2<\/td>\n<\/tr>\n
10<\/td>\nPrader-Willi Syndrome<\/a> <\/span><\/strong><\/td>\n3<\/td>\n8<\/td>\n<\/tr>\n
11<\/td>\nSotos Syndrome <\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
12<\/td>\nNoonan syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n2<\/td>\n<\/tr>\n
13<\/td>\n1p36 deletion syndrome <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
14<\/td>\n4p deletion syndrome<\/a> <\/span><\/strong><\/td>\n1<\/td>\n5<\/td>\n<\/tr>\n
15<\/td>\n5p deletion syndrome<\/a> <\/span><\/strong><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
16<\/td>\nSmith-Magenis syndrome <\/a> <\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
17<\/td>\n22q11.2 deletion syndrome<\/a> <\/span><\/strong><\/td>\n2<\/td>\n10<\/td>\n<\/tr>\n
18<\/td>\nEpstein syndrome<\/a><\/span><\/strong><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n25<\/td>\n118<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\nName of diseases<\/th>\nPatient<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nOther diseases<\/span><\/strong><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nBardet-Biedl syndrome<\/a> <\/strong><\/span><\/td>\n1<\/td>\n2<\/td>\n<\/tr>\n
2<\/td>\nCongenital Neutropenia, Kostmann syndrome<\/a> <\/strong><\/span><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
3<\/td>\nJuvenile nephronophthisis <\/a> <\/span><\/strong><\/td>\n2<\/td>\n6<\/td>\n<\/tr>\n
4<\/td>\nPendred Syndrome<\/a> <\/strong><\/span><\/td>\n3<\/td>\n3<\/td>\n<\/tr>\n
5<\/td>\nAlzheimer\u2019s disease <\/a> <\/strong><\/span><\/strong><\/td>\n19<\/td>\n24<\/td>\n<\/tr>\n
6<\/td>\nDementia of Alzheimer\u2019s type<\/a> <\/span><\/strong><\/td>\n1<\/td>\n7<\/td>\n<\/tr>\n
7<\/td>\nEpilepsy<\/a> <\/span><\/strong><\/td>\n7<\/td>\n10<\/td>\n<\/tr>\n
8<\/td>\nAge-related Macular Degeneration<\/a> <\/strong><\/span><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
9<\/td>\nBietti crystalline retinopathy<\/a> <\/strong><\/span><\/td>\n4<\/td>\n24<\/td>\n<\/tr>\n
10<\/td>\nMorphea with autoimmune hepatitis<\/a><\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
11<\/td>\nRheumatoid Arthritis <\/a> <\/strong><\/span><\/td>\n6<\/td>\n38<\/td>\n<\/tr>\n
12<\/td>\nReducing body myopathy <\/a> <\/strong><\/span><\/td>\n2<\/td>\n4<\/td>\n<\/tr>\n
13<\/td>\nBernard-Soulier syndorome<\/a> <\/strong><\/span><\/td>\n1<\/td>\n2<\/td>\n<\/tr>\n
14<\/td>\nLangerhans cell histiocytosis<\/a> <\/strong><\/span><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
15<\/td>\nRefractory nephrotic syndrome<\/a> <\/strong><\/span><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
16<\/td>\nMuro disease (Kii ALS\/PDC) <\/a> <\/strong><\/span><\/td>\n3<\/td>\n3<\/td>\n<\/tr>\n
17<\/td>\nRAS-associated autoimmune leukoproliferative disorder (RALD)<\/a> <\/strong><\/span><\/td>\n2<\/td>\n7<\/td>\n<\/tr>\n
18<\/td>\nAtopic dermatitis <\/a> <\/strong><\/span><\/td>\n1<\/td>\n1<\/td>\n<\/tr>\n
19<\/td>\nAllergic rhinitis (Pollen allergy)<\/a> <\/strong><\/span><\/td>\n1<\/td>\n1<\/td>\n<\/tr>\n
20<\/td>\nColorectal cancer<\/a><\/strong><\/span><\/td>\n3<\/td>\n22<\/td>\n<\/tr>\n
21<\/td>\nFulminant hepatitis<\/a> <\/strong><\/span><\/td>\n4<\/td>\n9<\/td>\n<\/tr>\n
22<\/td>\nFamilial atrial fibrillation \/ Sick sinus syndrome<\/a> <\/strong><\/span><\/td>\n4<\/td>\n4<\/td>\n<\/tr>\n
23<\/td>\nArrhythmogenic right ventricular cardiomyopathy (ARVC)<\/a> <\/strong><\/span><\/td>\n1<\/td>\n2<\/td>\n<\/tr>\n
24<\/td>\nPancreatitis<\/a> <\/strong><\/span><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
25<\/td>\nMyelodysplastic syndromes<\/a>\u00a0<\/strong><\/span><\/td>\n1<\/td>\n1<\/td>\n<\/tr>\n
26<\/td>\nLichen sclerosus et atrophicus<\/a> <\/strong><\/span><\/td>\n2<\/td>\n12<\/td>\n<\/tr>\n
27<\/td>\nProtein S deficiency<\/a> <\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
28<\/td>\nIntrahepatic stones<\/a> <\/strong><\/span><\/td>\n1<\/td>\n2<\/td>\n<\/tr>\n
29<\/td>\nSecondary antiphospholipid syndrome<\/a> <\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
30<\/td>\nOssification of anterior longitudinal ligament<\/a> <\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
31<\/td>\nPrimary aldosteronism<\/a> <\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
32<\/td>\nGuillain-Barr\u00e9 syndrome<\/a> <\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
33<\/td>\nDiffuse panbronchiolitis<\/a> <\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
34<\/td>\nMyelofibrosis<\/a> <\/strong><\/span><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
35<\/td>\nAicardi Goutiares syndrome<\/a>\u00a0<\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
36<\/td>\nMultiple endocrine neoplasia<\/a>\u00a0<\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
37<\/td>\nVon Hippel-Lindau disease<\/a><\/strong><\/span><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
38<\/td>\nHereditary pheochromocytoma\/ paraganglioma syndrome<\/a><\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
39<\/td>\nCongenital metabolic disorder<\/a>\u00a0<\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
40<\/td>\nNGLY1 deficiency<\/a>\u00a0<\/strong><\/span><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
41<\/td>\nAutism spectrum disorde<\/a>\u00a0<\/strong><\/span><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
42<\/td>\nCongenital diabetes insipidus<\/a>\u00a0<\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
43<\/td>\nDevelopmental delay, epilepsy, neonatal diabetes<\/a>\u00a0<\/strong><\/span><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
44<\/td>\nHypochondroplasia<\/a> <\/strong><\/span><\/td>\n2<\/td>\n3<\/td>\n<\/tr>\n
45<\/td>\nFamilial adenomatous polyposis<\/a>\u00a0<\/strong><\/span><\/td>\n2<\/td>\n6<\/td>\n<\/tr>\n
46<\/td>\nGastric cancer<\/a>\u00a0<\/strong><\/span><\/td>\n2<\/td>\n32<\/td>\n<\/tr>\n
47<\/td>\nRetinoblastoma<\/a>\u00a0<\/strong><\/span><\/td>\n3<\/td>\n46<\/td>\n<\/tr>\n
48<\/td>\nX-linked thrombocytopenia (XLT)<\/a><\/strong><\/span><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
49<\/td>\nSpastic paraplegia<\/a><\/strong><\/span><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
50<\/td>\nDownsyndrome<\/a><\/strong><\/span><\/td>\n2<\/td>\n6<\/td>\n<\/tr>\n
51<\/td>\nCongenital muscle type laminopathy<\/a><\/strong><\/span><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n116<\/td>\n478<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\n<\/th>\nPatients<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nHealthy relatives of patients<\/b><\/span><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\nHealthy relatives of patients (Miyoshi myopathy)<\/a><\/span><\/strong><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
2<\/td>\nHealthy relatives of patients (Danon disease)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n2<\/td>\n<\/tr>\n
3<\/td>\nHealthy relatives of patients (Hypertrophic cardiomyopathy (HCM))<\/a> <\/span><\/strong><\/td>\n1<\/td>\n2<\/td>\n<\/tr>\n
4<\/td>\nHealthy relatives of patients (Myotubular myopathy)<\/a><\/span><\/strong><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
5<\/td>\nHealthy relatives of patients (Branchio-oto-renal syndrome)<\/a><\/span><\/strong><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
6<\/td>\nHealthy relatives of patients (Diamond-Blackfan anemia)<\/a> <\/span><\/strong><\/td>\n1<\/td>\n12<\/td>\n<\/tr>\n
7<\/td>\nHealthy relatives of patients \uff08Epstein syndrome\uff09<\/a><\/span><\/strong><\/td>\n1<\/td>\n3<\/td>\n<\/tr>\n
8<\/td>\nHealthy relatives of patients (Rheumatoid Arthritis)<\/a><\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
9<\/td>\nHealthy relatives of patients (NGLY1 deficiency)<\/a><\/span><\/strong><\/td>\n5<\/td>\n30<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n13<\/td>\n64<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\n<\/th>\nPatients<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nHealthy individuals
\n(Clinical information is available only for users in Japan)<\/b><\/span><\/td>\n		<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\n30s\u3000Male<\/a><\/span><\/strong><\/td>\n10<\/td>\n60<\/td>\n<\/tr>\n
2<\/td>\n30s\u3000Female<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
3<\/td>\n40s\u3000Male<\/a><\/span><\/strong><\/td>\n10<\/td>\n60<\/td>\n<\/tr>\n
4<\/td>\n40s\u3000Female<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
5<\/td>\n50s\u3000Male<\/a><\/span><\/strong><\/td>\n10<\/td>\n59<\/td>\n<\/tr>\n
6<\/td>\n50s\u3000Female<\/a> <\/span><\/strong><\/td>\n3<\/td>\n17<\/td>\n<\/tr>\n
7<\/td>\n60s\u3000Male<\/a><\/span><\/strong><\/td>\n10<\/td>\n60<\/td>\n<\/tr>\n
8<\/td>\n70s\u3000Male<\/a><\/span><\/strong><\/td>\n8<\/td>\n47<\/td>\n<\/tr>\n
9<\/td>\n80s\u3000Male<\/a><\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n58<\/td>\n343<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
<\/th>\n<\/th>\nPatients<\/th>\nCell line<\/th>\n<\/tr>\n
<\/td>\nHealthy individuals<\/b><\/span><\/td>\n<\/td>\n<\/td>\n<\/tr>\n
1<\/td>\n10s\u3000Female<\/a><\/span><\/strong><\/td>\n1<\/td>\n1<\/td>\n<\/tr>\n
2<\/td>\n20s\u3000Male<\/a> <\/span><\/strong><\/td>\n1<\/td>\n1<\/td>\n<\/tr>\n
3<\/td>\n30s\u3000Male<\/a><\/span><\/strong><\/td>\n7<\/td>\n30<\/td>\n<\/tr>\n
4<\/td>\n40s\u3000Male<\/a> <\/span><\/strong><\/td>\n9<\/td>\n51<\/td>\n<\/tr>\n
5<\/td>\n40s\u3000Female<\/a><\/span><\/strong><\/td>\n7<\/td>\n38<\/td>\n<\/tr>\n
6<\/td>\n50s\u3000Male<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
6<\/td>\n50s\u3000Female<\/a> <\/span><\/strong><\/td>\n11<\/td>\n66<\/td>\n<\/tr>\n
7<\/td>\n60s\u3000Male<\/a> <\/span><\/strong><\/td>\n8<\/td>\n45<\/td>\n<\/tr>\n
9<\/td>\n60s\u3000Female<\/a><\/span><\/strong><\/td>\n6<\/td>\n27<\/td>\n<\/tr>\n
10<\/td>\n70s\u3000Male<\/a> <\/span><\/strong><\/td>\n3<\/td>\n18<\/td>\n<\/tr>\n
11<\/td>\n70s\u3000Female<\/a><\/span><\/strong><\/td>\n2<\/td>\n10<\/td>\n<\/tr>\n
12<\/td>\n80s\u3000Female<\/a><\/span><\/strong><\/td>\n1<\/td>\n6<\/td>\n<\/tr>\n
<\/td>\nTotal<\/td>\n59<\/td>\n311<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"

\uff0a When you want to use some Disease-specific iPS cells, please e-mail to the following address. \uff0a In relation to the information that are not described below, please e-mail to the following address. Contact us :\u00a0cellips.brcriken.jp Blue letter cells are available. You obtain the information by clicking the blue letter. *iPS cells created using the Sendai virus vector are now available Genetic analysis of disease-specific iPS cells carried out in RIKEN BRC. \u30fbAmyotrophic lateral sclerosis (ALS) \u30fbSpinocerebellar degeneration *Terms: In relation to all iPS cell lines, approval of institutional review board and\/or institutional ethical committee regarding the research using iPS cells is necessary. In relation to all iPS cell lines, commercial use is prohibited. In relation to the cell lines marked with \u25ce, (1) the recipient does not need to obtain an approval from the depositor, (2) there is no need of collaboration with the depositor, and (3) for-profit entities can also utilize. Update : 2020.11.27<\/p>\n","protected":false},"author":15,"featured_media":0,"parent":148,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_seopress_robots_primary_cat":"","_seopress_titles_title":"","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_analysis_target_kw":"","footnotes":"","_wp_rev_ctl_limit":""},"class_list":["post-10124","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/comments?post=10124"}],"version-history":[{"count":19,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10124\/revisions"}],"predecessor-version":[{"id":10842,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/10124\/revisions\/10842"}],"up":[{"embeddable":true,"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/pages\/148"}],"wp:attachment":[{"href":"http:\/\/cell.brc.riken.jp\/en\/wp-json\/wp\/v2\/media?parent=10124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}